Genentech

NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling

Analysis of Tumor Mutation, Treatment Data Across Cancers Points to Predictive Biomarkers

NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold

FDA Asks Industry to Come Up With Plans to Address Diversity in Drug, Diagnostic Trials

Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial

Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials

UK's NICE Recommends Against Merck's Keytruda, Chemo Combo for Advanced PD-L1-Positive TNBC

NICE Recommends Seagen's Tukysa for Advanced HER2-Positive Breast Cancer in England

Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps

FDA Approves Genentech's Rituxan, Chemo for CD20-Positive Pediatric Leukemia, Lymphoma Patients

FDA Approves Genentech's Tecentriq as Adjuvant Treatment for PD-L1-Expressing NSCLC

Molecular Clonal Tracking Method Captures Lung Cancer Treatment Response, Resistance Features

In Brief This Week: IASO Biotherapeutics, Genentech, BioNTech

Genentech Basket Trial Identifies Impact of Co-Mutations in Dual HER2-Targeted Treatment Response

Blueprint Medicines, Genentech to Discuss With Regulators Gavreto's Activity in RET-Altered Tumors

FDA Expert Panel Votes to Keep Tecentriq Accelerated Approval for Certain Bladder Cancer Patients